PMID- 30041763
OWN - NLM
STAT- MEDLINE
DCOM- 20190102
LR  - 20190102
IS  - 2410-8650 (Electronic)
IS  - 1607-551X (Linking)
VI  - 34
IP  - 8
DP  - 2018 Aug
TI  - Pre-treatment with proton pump inhibitors decreases the success of primary 
      Helicobacter pylori eradication using a vonoprazan-based regimen.
PG  - 456-460
LID - S1607-551X(17)30892-6 [pii]
LID - 10.1016/j.kjms.2018.03.009 [doi]
AB  - Vonoprazan-based regimens have improved the rate of successful Helicobacter 
      pylori (H. pylori) eradication, but it has not reached 100%. The aim of this 
      study is to clarify significant predictors of successful H. pylori eradication 
      using a vonoprazan-based regimen. In this retrospective cohort study, 174 
      patients who underwent primary H. pylori eradication therapy were included. All 
      patients underwent esophagogastroduodenoscopy before treatment. The 
      vonoprazan-based regimen includes amoxicillin 750 mg, clarithromycin 200 mg and 
      vonoprazan 20 mg twice daily for one week. Pre-treatment with a proton pump 
      inhibitor (PPI) was defined as continued PPI use for more than four weeks prior 
      to eradication therapy. The rates of successful eradication were 83% (145/174) in 
      intention-to-treat analysis and 85% (145/171) in per-protocol analysis. 
      Predictors of successful eradication among 171 patients were evaluated in 
      per-protocol analysis. In univariate analysis, male gender was a significant 
      positive predictor of successful eradication (odds ratio [OR] 3.813, 95% 
      confidence interval [CI] 1.363-10.663, p = 0.010) and pre-treatment with PPIs was 
      a negative predictor (OR 0.193, 95%CI 0.076-0.485, p < 0.001). In multivariate 
      analysis, male gender remained a positive predictor (OR 3.826, 95%CI 
      1.317-11.116, p = 0.013), and pre-treatment with PPIs (OR 0.232, 95%CI 
      0.087-0.615, p = 0.003) remained a negative predictor. In conclusion, 
      pre-treatment with PPIs before eradication therapy decreases the rate of 
      successful eradication. Therefore, it may be desirable to discontinue 
      pre-treatment with PPIs prior to eradication therapy, because of the potential to 
      improve the rate of successful eradication.
CI  - Copyright (c) 2018. Published by Elsevier Taiwan LLC.
FAU - Shinozaki, Satoshi
AU  - Shinozaki S
AD  - Shinozaki Medical Clinic, Utsunomiya, Japan; Division of Gastroenterology, 
      Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
FAU - Osawa, Hiroyuki
AU  - Osawa H
AD  - Division of Gastroenterology, Department of Medicine, Jichi Medical University, 
      Shimotsuke, Japan. Electronic address: osawa@jichi.ac.jp.
FAU - Sakamoto, Hirotsugu
AU  - Sakamoto H
AD  - Division of Gastroenterology, Department of Medicine, Jichi Medical University, 
      Shimotsuke, Japan.
FAU - Hayashi, Yoshikazu
AU  - Hayashi Y
AD  - Division of Gastroenterology, Department of Medicine, Jichi Medical University, 
      Shimotsuke, Japan.
FAU - Kobayashi, Yasutoshi
AU  - Kobayashi Y
AD  - Division of Gastroenterology, Department of Medicine, Jichi Medical University, 
      Shimotsuke, Japan.
FAU - Miura, Yoshimasa
AU  - Miura Y
AD  - Division of Gastroenterology, Department of Medicine, Jichi Medical University, 
      Shimotsuke, Japan.
FAU - Lefor, Alan Kawarai
AU  - Lefor AK
AD  - Department of Surgery, Jichi Medical University, Shimotsuke, Japan.
FAU - Yamamoto, Hironori
AU  - Yamamoto H
AD  - Division of Gastroenterology, Department of Medicine, Jichi Medical University, 
      Shimotsuke, Japan.
LA  - eng
PT  - Journal Article
DEP - 20180413
PL  - China (Republic : 1949- )
TA  - Kaohsiung J Med Sci
JT  - The Kaohsiung journal of medical sciences
JID - 100960562
RN  - 0 
      (1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Pyrroles)
RN  - 0 (Sulfonamides)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amoxicillin/therapeutic use
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Clarithromycin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Helicobacter Infections/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Pyrroles/*therapeutic use
MH  - Retrospective Studies
MH  - Sulfonamides/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - Outcome measure
OT  - Potassium-competitive acid blocker
OT  - Proton pump inhibitors
EDAT- 2018/07/26 06:00
MHDA- 2019/01/03 06:00
CRDT- 2018/07/26 06:00
PHST- 2017/12/19 00:00 [received]
PHST- 2018/01/25 00:00 [revised]
PHST- 2018/03/26 00:00 [accepted]
PHST- 2018/07/26 06:00 [entrez]
PHST- 2018/07/26 06:00 [pubmed]
PHST- 2019/01/03 06:00 [medline]
AID - S1607-551X(17)30892-6 [pii]
AID - 10.1016/j.kjms.2018.03.009 [doi]
PST - ppublish
SO  - Kaohsiung J Med Sci. 2018 Aug;34(8):456-460. doi: 10.1016/j.kjms.2018.03.009. 
      Epub 2018 Apr 13.